{"id":37895,"date":"2026-07-07T19:54:46","date_gmt":"2026-07-07T19:54:46","guid":{"rendered":"https:\/\/selmiswiss.com\/?post_type=product&#038;p=37895"},"modified":"2026-07-07T20:00:44","modified_gmt":"2026-07-07T20:00:44","slug":"retatrutide-20-mg","status":"publish","type":"product","link":"https:\/\/selmiswiss.com\/en\/product\/retatrutide-20-mg\/","title":{"rendered":"Retatrutide 20 mg"},"content":{"rendered":"<div class=\"selmi-peptide-sheet\">\n<div class=\"selmi-peptide-header\">\n<div class=\"selmi-peptide-title\">Retatrutide<\/div>\n<div class=\"selmi-peptide-category\">Weight Loss \/ Metabolism<\/div>\n<\/p><\/div>\n<div class=\"selmi-peptide-grid selmi-peptide-grid-top\">\n<section class=\"selmi-peptide-main\">\n<div class=\"selmi-peptide-section\">\n<h3>MECHANISM OF ACTION<\/h3>\n<p>Triple agonist: GLP-1R for satiety and insulin secretion; GIPR for glucose-dependent insulin secretion and energy expenditure through activation of brown adipose tissue; and the glucagon receptor for energy expenditure, lipolysis, and normalization of hepatic glucose production. The GIP base conjugated with a fatty acid extends the half-life. Triple-receptor activation provides a superior metabolic effect compared to dual agonists.  <\/p>\n<\/p><\/div>\n<div class=\"selmi-peptide-section\">\n<h3>KEY BENEFITS<\/h3>\n<ul>\n<li>Body weight reduction of up to 24% in Phase II trials; the most potent in its class.<\/li>\n<li>Greater reduction in body fat compared to tirzepatide.<\/li>\n<li>Improved glycemic control through multiple mechanisms.<\/li>\n<li>Improvement in cardiovascular risk factors.<\/li>\n<li>Potential for treating NASH and reducing liver fat.<\/li>\n<\/ul><\/div>\n<\/section>\n<aside class=\"selmi-peptide-dosing\">\n<h3>THE RESULTS DESCRIBED WERE OBTAINED BY FOLLOWING THE DOSAGE AND PROTOCOL SET FORTH BELOW<\/h3>\n<h4>2\u201312 mg once a week subcutaneously, titrated starting at 2 mg<\/h4>\n<p><strong>Vial size:<\/strong><br \/>10 mg<\/p>\n<p><strong>Frequency:<\/strong><br \/>Once a week<\/p>\n<p><strong>IU \/ Dose:<\/strong><br \/>40 IU = 2 mg initial dose<\/p>\n<p><strong>Reconstitution:<\/strong><br \/>Reconstitute with 2 mL of bacteriostatic water. 40 IU = 2 mg initial dose. Administer weekly.  <\/p>\n<p><strong>Cycle:<\/strong><br \/>Chronic use according to obesity medicine protocol. Titration over 12\u201320 weeks. <\/p>\n<\/aside><\/div>\n<div class=\"selmi-peptide-grid selmi-peptide-grid-info\">\n<section class=\"selmi-peptide-box\">\n<h3>SIDE EFFECTS AND SAFETY<\/h3>\n<p>Prominent gastrointestinal side effects, such as nausea, vomiting, and diarrhea. Its action on the glucagon receptor leads to increased energy expenditure and possible mild hyperglycemia at the start of treatment. Titration minimizes intolerance.  <\/p>\n<\/section>\n<section class=\"selmi-peptide-box selmi-peptide-box-alt\">\n<h3>RESEARCH AND CLINICAL NOTES<\/h3>\n<p>Jastreboff et al. (NEJM 2023): 24.2% reduction in body weight at 48 weeks with the highest dose; the highest result to date in a weight-loss drug trial. Phase III TRIUMPH trial ongoing. Compound under development by Eli Lilly.   <\/p>\n<\/section><\/div>\n<section class=\"selmi-peptide-profile\">\n<h3>TARGET PROFILE:<\/h3>\n<p><em>Obesity Medicine, Endocrinology, and Weight Loss.<\/em><\/p>\n<\/section>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<div class=\"selmi-div-disclaimer\"><span class=\"selmi-disclaimer-text\">FOR PRECLINICAL RESEARCH USE ONLY \u2014 NOT APPROVED FOR HUMAN USE.<\/span><\/div>\n<ul>\n<li>Body weight reduction of up to 24% in Phase II trials; the most potent in its class.<\/li>\n<li>Greater reduction in body fat compared to tirzepatide.<\/li>\n<li>Improved glycemic control through multiple mechanisms.<\/li>\n<li>Improvement in cardiovascular risk factors.<\/li>\n<li>Potential for treating NASH and reducing liver fat.<\/li>\n<\/ul>\n","protected":false},"featured_media":37901,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[1115],"product_tag":[1101],"class_list":["post-37895","product","type-product","status-publish","has-post-thumbnail","product_cat-obesity-metabolism-peptides","product_tag-peptides","first","instock","taxable","shipping-taxable","purchasable","product-type-simple"],"acf":[],"_links":{"self":[{"href":"https:\/\/selmiswiss.com\/en\/wp-json\/wp\/v2\/product\/37895","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/selmiswiss.com\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/selmiswiss.com\/en\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/selmiswiss.com\/en\/wp-json\/wp\/v2\/comments?post=37895"}],"version-history":[{"count":1,"href":"https:\/\/selmiswiss.com\/en\/wp-json\/wp\/v2\/product\/37895\/revisions"}],"predecessor-version":[{"id":37905,"href":"https:\/\/selmiswiss.com\/en\/wp-json\/wp\/v2\/product\/37895\/revisions\/37905"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/selmiswiss.com\/en\/wp-json\/wp\/v2\/media\/37901"}],"wp:attachment":[{"href":"https:\/\/selmiswiss.com\/en\/wp-json\/wp\/v2\/media?parent=37895"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/selmiswiss.com\/en\/wp-json\/wp\/v2\/product_brand?post=37895"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/selmiswiss.com\/en\/wp-json\/wp\/v2\/product_cat?post=37895"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/selmiswiss.com\/en\/wp-json\/wp\/v2\/product_tag?post=37895"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}